Women who have Cancer Cancer in one breast may be more likely to develop in the opposite breast if they are specific. Genetic changes which predicts their development. Breast cancerAccording to a study led by the Mayo Clinic Comprehensive Cancer Center. According to the authors of the study, the results of the study, published in the Journal of Clinical Oncology, will help to personalize the approach to breast cancer screening and risk factors. (Also read: Breast Cancer Awareness Month 2022: Early signs of breast cancer and when to get tested to stay safe. )
The study used data from 15,104 women prospectively enrolled in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. The researchers found that patients who carry a germ-line BRCA1, BRCA2 or CHEK2 mutation have at least a two-fold increased risk of developing cancer in both breasts, known as contralateral breast cancer.
In contrast, patients carrying a germline ATM mutation did not have a significantly elevated risk of contralateral breast cancer. Among PALB2 carriers, the risk of contralateral breast cancer was significantly increased only in those with estrogen receptor-negative disease.
“These are the first population-based studies for these three genes beyond BRCA1/2,” said Fergus Couch, PhD, Zbigniew and Anna M. Schiller Professor of Breast Cancer Research at the Mayo Clinic Comprehensive Cancer Center. of Medical Research and Principal says. Investigators of the CARRIERS study. “This is one of the largest studies to provide age-adjusted breast cancer risk estimates by race/ethnicity at diagnosis, menopausal status and germline mutation carriers.”
Most breast cancer patients who carry genetic mutations assume they have a higher risk of developing cancer in the opposite breast, says co-author Siddhartha Yadav, MD, medical oncologist, Mayo Clinic Comprehensive Cancer Center. . Although this is true for BRCA1/2 mutation carriers with breast cancer, a disproportionate breast cancer risk in carriers of germline mutations in ATM, CHEK2 or PALB2 has not been previously established. Even for BRCA1/2 carriers, a comprehensive assessment of breast cancer risk stratified by age, estrogen receptor status, menopausal status, and the effects of early breast cancer treatment has not been performed.
“The findings reveal important information that will help in personalized assessment of breast cancer risk in our patients who carry the germline mutation,” says Dr. Yadav. “Having this level of detail will help guide decisions about appropriate screening among patients and their care teams and reduce the risk of invasive breast cancer based on more accurate and individualized risk estimates.” Steps will be taken.”
Researchers found that premenopausal women who carry germline mutations generally have a higher risk of contralateral breast cancer than women who are diagnosed with breast cancer after menopause. Among women with genetic mutations in breast cancer-prone genes, black women and non-Hispanic white women have a similar increased risk of contralateral breast cancer, the study suggests. Should be the same.
“Many women will undergo a bilateral mastectomy to reduce the chance of a second breast cancer,” says Dr. Couch. “Now we have the data to work with when deciding whether to remove the other breast, do aggressive surveillance or take preventive medication.”
This story was published without editing the text from a wire agency feed. Only the title has been changed.